346 related articles for article (PubMed ID: 17495322)
21. A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis.
Medicherla S; Ma JY; Mangadu R; Jiang Y; Zhao JJ; Almirez R; Kerr I; Stebbins EG; O'Young G; Kapoun AM; Luedtke G; Chakravarty S; Dugar S; Genant HK; Protter AA
J Pharmacol Exp Ther; 2006 Jul; 318(1):132-41. PubMed ID: 16597712
[TBL] [Abstract][Full Text] [Related]
22. A unique pathway in the homing of murine multiple myeloma cells: CD44v10 mediates binding to bone marrow endothelium.
Asosingh K; Günthert U; De Raeve H; Van Riet I; Van Camp B; Vanderkerken K
Cancer Res; 2001 Apr; 61(7):2862-5. PubMed ID: 11306459
[TBL] [Abstract][Full Text] [Related]
23. Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes.
Medicherla S; Protter AA; Ma JY; Mangadu R; Almirez R; Koppelman B; Kerr I; Navas TA; Movius F; Reddy M; Liu YW; Luedtke G; Perumattam J; Mavunkel B; Dugar S; Schreiner GF
J Pharmacol Exp Ther; 2006 Jul; 318(1):99-107. PubMed ID: 16603672
[TBL] [Abstract][Full Text] [Related]
24. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
Hideshima T; Podar K; Chauhan D; Ishitsuka K; Mitsiades C; Tai YT; Hamasaki M; Raje N; Hideshima H; Schreiner G; Nguyen AN; Navas T; Munshi NC; Richardson PG; Higgins LS; Anderson KC
Oncogene; 2004 Nov; 23(54):8766-76. PubMed ID: 15480425
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors of protein kinase C sensitise multiple myeloma cells to common genotoxic drugs.
Baumann P; Armann J; Mandl-Weber S; Grün G; Oduncu F; Schmidmaier R
Eur J Haematol; 2008 Jan; 80(1):37-45. PubMed ID: 18028419
[TBL] [Abstract][Full Text] [Related]
26. The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.
Deleu S; Lemaire M; Arts J; Menu E; Van Valckenborgh E; King P; Vande Broek I; De Raeve H; Van Camp B; Croucher P; Vanderkerken K
Leukemia; 2009 Oct; 23(10):1894-903. PubMed ID: 19494837
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow.
Yamashita K; Iwasaki T; Tsujimura T; Sugihara A; Yamada N; Ueda H; Okamura H; Futani H; Maruo S; Terada N
Oncol Rep; 2002; 9(6):1237-44. PubMed ID: 12375027
[TBL] [Abstract][Full Text] [Related]
28. p38 MAP kinase inhibitors: many are made, but few are chosen.
Dominguez C; Powers DA; Tamayo N
Curr Opin Drug Discov Devel; 2005 Jul; 8(4):421-30. PubMed ID: 16022178
[TBL] [Abstract][Full Text] [Related]
29. Migration, adhesion and differentiation of malignant plasma cells in the 5T murine model of myeloma.
Asosingh K
Verh K Acad Geneeskd Belg; 2003; 65(2):127-34. PubMed ID: 12870183
[TBL] [Abstract][Full Text] [Related]
30. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.
Gunn WG; Conley A; Deininger L; Olson SD; Prockop DJ; Gregory CA
Stem Cells; 2006 Apr; 24(4):986-91. PubMed ID: 16293576
[TBL] [Abstract][Full Text] [Related]
31. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
32. Interaction between a murine myeloma cell line and bone marrow stromal cells.
Bradley TR; Kriegler AB; Verschoor SM; Tzelepis SM; Cooper IA
Exp Hematol; 1996 Feb; 24(2):307-9. PubMed ID: 8641357
[TBL] [Abstract][Full Text] [Related]
33. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
[TBL] [Abstract][Full Text] [Related]
34. Dickkopf-1: a suitable target for the management of myeloma bone disease.
Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
[TBL] [Abstract][Full Text] [Related]
35. Pathophysiology of multiple myeloma bone disease.
Lentzsch S; Ehrlich LA; Roodman GD
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1035-49, viii. PubMed ID: 17996587
[TBL] [Abstract][Full Text] [Related]
36. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
Martin SK; Gan ZY; Fitter S; To LB; Zannettino AC
Leuk Res; 2015 Mar; 39(3):380-7. PubMed ID: 25624048
[TBL] [Abstract][Full Text] [Related]
37. Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
Buckle CH; De Leenheer E; Lawson MA; Yong K; Rabin N; Perry M; Vanderkerken K; Croucher PI
PLoS One; 2012; 7(8):e41127. PubMed ID: 22952578
[TBL] [Abstract][Full Text] [Related]
38. The use of animal models in multiple myeloma.
Libouban H
Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798
[TBL] [Abstract][Full Text] [Related]
39. p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation.
Medicherla S; Fitzgerald MF; Spicer D; Woodman P; Ma JY; Kapoun AM; Chakravarty S; Dugar S; Protter AA; Higgins LS
J Pharmacol Exp Ther; 2008 Mar; 324(3):921-9. PubMed ID: 18056868
[TBL] [Abstract][Full Text] [Related]
40. SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.
Heusschen R; Muller J; Binsfeld M; Marty C; Plougonven E; Dubois S; Mahli N; Moermans K; Carmeliet G; Léonard A; Baron F; Beguin Y; Menu E; Cohen-Solal M; Caers J
Oncotarget; 2016 May; 7(21):30712-29. PubMed ID: 27095574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
